Humira Biosimilars: Which Are Covered by Insurance and What Do They Cost?
If you take Humira (adalimumab) for rheumatoid arthritis, Crohn's disease, psoriasis, or another condition, you've likely heard that biosimilar versions are now available in the U.S. That's a significant shift — and it raises real questions about what your insurance will cover, what you'll actually pay, and whether switching makes sense.
Here's a clear look at how Humira biosimilars work, how coverage decisions get made, and what shapes your out-of-pocket costs.
What Is a Biosimilar, and How Is It Different From a Generic?
A biosimilar is not a generic drug in the traditional sense. Generics are chemically identical copies of small-molecule drugs. Biologics like Humira are large, complex proteins made from living cells — and you can't copy them the way you'd copy a simple chemical compound.
A biosimilar is a version that has been shown to have no clinically meaningful differences in safety, purity, or effectiveness compared to the original biologic. The FDA approves biosimilars through a rigorous review process, and many are also designated interchangeable — meaning a pharmacist may be able to substitute one for the other without a new prescription, depending on your state's laws.
This matters because it directly affects how insurers treat biosimilars on their formularies.
How Many Humira Biosimilars Are There?
As of 2023 and into 2024, more than a dozen adalimumab biosimilars have received FDA approval and launched in the U.S. market — making this one of the largest biosimilar launches in American pharmaceutical history. Brand names include products like Hadlima, Hyrimoz, Cyltezo, Yusimry, Simlandi, Hulio, and several others.
Some of these are citrate-free (like Humira's current formulation, which tends to cause less injection-site discomfort) and available in both low-concentration and high-concentration forms. These formulation details can matter when your doctor evaluates which version is appropriate for your dose and administration method.
Not all of these biosimilars are available at every pharmacy or through every specialty pharmacy network — which is one reason your specific coverage situation may differ significantly from someone else's.
Which Humira Biosimilar Will Your Insurance Cover? 💊
This is where things get individual quickly. Insurance plans — including commercial plans, Medicare Part D, and Medicaid — each maintain their own formulary, which is the list of covered drugs and their cost-sharing tiers.
Several factors determine which biosimilar(s) your plan covers:
- Formulary placement: Some plans have moved Humira itself to a higher tier (meaning higher cost-sharing) while placing one or more biosimilars on a preferred, lower-cost tier. Others continue to cover Humira preferentially.
- Rebate agreements: Insurers and pharmacy benefit managers (PBMs) negotiate rebates with manufacturers. A biosimilar that offers larger rebates to the PBM may end up on the preferred tier — even if it isn't the lowest-priced option at the pharmacy counter.
- Interchangeability status: Biosimilars with FDA interchangeable designation may receive different formulary treatment than those without it.
- Specialty pharmacy requirements: Many biologics must be dispensed through a designated specialty pharmacy, and your plan may only cover certain biosimilars through its contracted network.
The bottom line: There is no single answer to "which biosimilar is covered." It depends entirely on your specific health plan and its current formulary — which can change at open enrollment or even mid-year with notice.
What Do Humira Biosimilars Cost?
Cost is layered, and it helps to separate list price from what you actually pay.
List Price
Biosimilar manufacturers have launched their products at a range of price points relative to Humira's list price — some at modest discounts, others at substantially steeper discounts. However, list price rarely reflects what most insured patients pay.
What Insured Patients Typically Pay
Your out-of-pocket cost depends on:
| Factor | How It Affects Your Cost |
|---|---|
| Plan tier placement | Lower tier = lower copay or coinsurance |
| Deductible status | Before deductible is met, you may pay a larger share |
| Coinsurance vs. copay | Coinsurance (a percentage) can be very high for specialty drugs |
| Out-of-pocket maximum | Once reached, most costs stop for the year |
| Manufacturer assistance | Patient assistance programs can reduce cost significantly |
For many people on commercial insurance, specialty drug cost-sharing — whether for Humira or a biosimilar — can run into hundreds of dollars per month before any assistance programs apply.
Manufacturer Patient Assistance Programs
Both the makers of brand-name Humira and several biosimilar manufacturers offer copay assistance cards or patient assistance programs for eligible patients. These can substantially reduce or even eliminate out-of-pocket costs for commercially insured patients who qualify. These programs are generally not available to people enrolled in Medicare or Medicaid.
Medicare and Medicaid
If you're on Medicare Part D, your costs depend on your specific plan's formulary and what phase of the benefit you're in. The Inflation Reduction Act has introduced changes to Part D cost-sharing for high-cost drugs, which may affect how much people on Medicare ultimately pay for biologics over a benefit year.
For Medicaid enrollees, coverage and cost-sharing vary by state, but out-of-pocket costs are typically low.
Can Your Doctor Prescribe a Specific Biosimilar? 🩺
Yes. Your prescriber can specify which formulation they want, and in many cases, a prescriber can indicate that substitution is not permitted — which may matter if you've been stable on a particular product. If a plan's preferred biosimilar isn't the one your doctor wants to prescribe, a prior authorization or step therapy process may be required to justify coverage of a different option.
This is an area where working closely with your prescriber and your insurer — or asking your specialty pharmacy to help navigate — can make a real difference.
What to Check Before Your Next Refill
If you're currently on Humira or being newly prescribed adalimumab, here's what's worth looking into:
- Your plan's current formulary: Check which adalimumab product is on the preferred tier and what the cost-sharing looks like at each tier.
- Whether your plan has moved Humira to non-preferred status: Some plans have restructured their formularies specifically around biosimilar adoption.
- Manufacturer savings programs: Check the website of whichever product your doctor prescribes for available assistance programs.
- Your specialty pharmacy options: Confirm which pharmacies are in-network for your plan and which products they carry.
- State laws on interchangeability: If you're concerned about automatic substitution at the pharmacy, your state's rules — and your prescriber's instructions — determine whether that can happen.
The Landscape Is Still Evolving
The Humira biosimilar market is relatively new and changing. Formulary decisions, pricing structures, and manufacturer assistance programs continue to shift as competition plays out. What was true about your plan's coverage six months ago may not reflect your current formulary.
For anyone managing a chronic condition that depends on this medication, the key is understanding the variables — then checking your specific plan, your prescriber's preference, and what assistance programs apply to your situation. No two patients will have exactly the same cost picture.
